Financial results for the third quarter and YTD September 2025 for Medistim ASA

24 Oct 2025 08:30 CEST

Another strong quarter for sales revenues with 25.7 % growth, ending at MNOK
166.8 (MNOK 132.8). Record sales revenue year to date September with 25.8 %
growth, ending at MNOK 517.5 (MNOK 411.5). Currency neutral sales of own
products were up 29.8 % for the quarter and 28.0 % year to date September.

Strong currency neutral growth for the quarter in AMERICAS and APAC, up 35.7 %
and 194 % respectively. EMEA down 11.8 %, yet up 1 % year to date September.

Third-party distributor sales in Scandinavia increased 4.4 % for the quarter and
16.2 % year to date September.

Operating profit (EBIT) grew by 27.1 % for the quarter and ended at MNOK 40.6,
resulting in 24.3 % EBIT margin (MNOK 31.9, 24.0 % margin). Year to date
September profit grew 46.2 % ending at a record MNOK 153.9, and 29.7 % EBIT
margin (MNOK 105.2, 25.6 % margin).

Recurring sales remained high, but strong capital sales reduce recurring sales
in % to 69.3% (73.7 %) compared to YTD September last year.

Solid cash position at quarter end with MNOK 157.6 after paying a dividend of
NOK 6.00 per share (NOK 4.5), total MNOK 109.5 in May (MNOK 82.4). No
interest-bearing

More information:
Access the news on Oslo Bors NewsWeb site

657883_Q3 2025 PPT presentation FINAL.pdf
657883_Q3 2025 Financial Report-Final.pdf